Literature DB >> 24820802

[Drug reactions caused by chemotherapy agents].

L M Ehmann1, H Schrumpf, P A Gerber, B Homey.   

Abstract

In recent years, several new classes of compounds have successfully been established in the treatment of cancer. They selectively inhibit disturbed signaling pathways or induce anti-tumor immune responses. These novel targeted cancer drugs show a favorable safety profile compared to conventional chemotherapeutic agents. The most important side effects of these anticancer agents include cutaneous reactions and occur in a time-dependant manner and show class-specific patterns. In this review article, we compare the cutaneous side effects of epidermal growth factor inhibitors (EGFRI), multikinase inhibitors (MKI), BRAF inhibitors (BRAFI), mTor inhibitors (mTorI) and immune checkpoint inhibitors and discuss severity-adapted management strategies.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24820802     DOI： 10.1007/s00105-013-2699-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  28 in total

1.  Ultraviolet A and photosensitivity during vemurafenib therapy.

Authors:  Reinhard Dummer; Jeannine Rinderknecht; Simone M Goldinger
Journal:  N Engl J Med       Date:  2012-02-02       Impact factor: 91.245

2.  Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus.

Authors:  Peter Arne Gerber; Bettina Alexandra Buhren; Ferda Cevikbas; Edwin Bölke; Martin Steinhoff; Bernhard Homey
Journal:  J Am Acad Dermatol       Date:  2010-07       Impact factor: 11.527

Review 3.  [Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects].

Authors:  P A Gerber; B A Buhren; S Kürle; B Homey
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

4.  Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients.

Authors:  Peter Arne Gerber; Stephan Meller; Tatiana Eames; Bettina Alexandra Buhren; Holger Schrumpf; Sonja Hetzer; Laura Maximiliane Ehmann; Wilfried Budach; Edwin Bölke; Christiane Matuschek; Andreas Wollenberg; Bernhard Homey
Journal:  Eur J Med Res       Date:  2012-02-23       Impact factor: 2.175

Review 5.  Cutaneous side-effects of EGFR inhibitors and their management.

Authors:  L M Ehmann; T Ruzicka; A Wollenberg
Journal:  Skin Therapy Lett       Date:  2011-01

Review 6.  Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.

Authors:  Katharina C Kähler; Axel Hauschild
Journal:  J Dtsch Dermatol Ges       Date:  2010-11-17       Impact factor: 5.584

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.

Authors:  Bruno Vincenzi; Daniele Santini; Antonio Russo; Raffaele Addeo; Francesco Giuliani; Liliana Montella; Sergio Rizzo; Olga Venditti; Anna Maria Frezza; Michele Caraglia; Giuseppe Colucci; Salvatore Del Prete; Giuseppe Tonini
Journal:  Oncologist       Date:  2010-01-05

Review 9.  Side effects of systemic oncological therapies in dermatology.

Authors:  Lisa Zimmer; Julia Vaubel; Elisabeth Livingstone; Dirk Schadendorf
Journal:  J Dtsch Dermatol Ges       Date:  2012-05-09       Impact factor: 5.584

10.  Epidermal EGFR controls cutaneous host defense and prevents inflammation.

Authors:  Beate M Lichtenberger; Peter A Gerber; Martin Holcmann; Bettina A Buhren; Nicole Amberg; Viktoria Smolle; Holger Schrumpf; Edwin Boelke; Parinaz Ansari; Colin Mackenzie; Andreas Wollenberg; Andreas Kislat; Jens W Fischer; Katharina Röck; Jürgen Harder; Jens M Schröder; Bernhard Homey; Maria Sibilia
Journal:  Sci Transl Med       Date:  2013-08-21       Impact factor: 17.956
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.